1.90% -0.0487

미네르바 뉴로사이언스 (NERV)

Minerva Neurosciences Inc 주식(NERV)의 최신 뉴스

미네르바 뉴로사이언스 (NERV)

Minerva Neurosciences Inc 주식(NERV)의 최신 뉴스

What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register? - Yahoo Lifestyle Australia

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com - Defense World

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? - Yahoo Singapore News

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? - Yahoo Singapore News

Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock? - Zacks Investment Research

Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?

HC Wainwright Brokers Reduce Earnings Estimates for Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World

Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Singapore News

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Yahoo Finance

Minerva mauled over roluperidone CRL - The Pharma Letter

Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Crude Oil Gains 1%; Macy's Plans To Close 150 Stores

Nasdaq Rises 50 Points; Lowe's Earnings Top Views

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for ... - Yahoo Finance

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Minerva Neurosciences: Q4 Earnings Snapshot - Quartz

FDA Action Alert: Alvotech and Minerva - BioSpace

5 FDA Decisions to Watch in Q1 - BioSpace

Minerva Neurosciences | INN - Investing News Network

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market - Yahoo Finance

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead - Seeking Alpha

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates - Yahoo Finance

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of ... - GlobeNewswire

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript - Insider Monkey

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA - Yahoo Finance

Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate - Yahoo Finance

Minerva Neurosciences Inc (NASDAQ: NERV) Submits New Drug Application for Roluperidone In Treating Negative ... - BP Journal

Billionaire Steven Cohen Just Made a Big Bet on Minerva Neurosciences (NERV) Stock - InvestorPlace

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates - GlobeNewswire

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned ... - GlobeNewswire

Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates - Yahoo News UK

Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session - Yahoo Singapore News

Minerva Neurosciences' roluperidone fails in Phase III study - Clinical Trials Arena

Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals - TipRanks.com - TipRanks

EX-99.1 - SEC.gov

Minerva Neurosciences: NERV Stock Plummets 72% on Schizophrenia Study - InvestorPlace

Minerva Neurosciences shares crushed under depression flop, development halted - Fierce Biotech

Moving Average Crossover Alert: Minerva Neurosciences - Yahoo Movies Canada

A Look At The Competitors To Minerva's Roluperidone (NASDAQ:NERV) - Seeking Alpha

Minerva Neurosciences (NERV) Earnings Date and Reports 2024 - MarketBeat

Minerva Neurosciences (NERV) Stock Forecast and Price Target 2024 - MarketBeat

NERV Stock Price and Chart — NASDAQ:NERV — TradingView - TradingView

Minerva Neurosciences Q1 loss per share $0.30 - Reuters

Minerva Neurosciences (NERV) Stock Price, News & Analysis - MarketBeat

NERV과 유사한 종목